Connecting clinical care, data and research
PartnershipsContact
← Back to publications

RESEARCH PUBLICATION / 2024

Original Article

GLP-1 receptor agonists and long-term outcomes of cirrhosis and diabetes mellitus

Glucagon-like Peptide-1 Receptor Agonist Use in Patients With Liver Cirrhosis and Type 2 Diabetes.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association

Citation & Authors

Clin Gastroenterol Hepatol. 2024;22(6):1255-1264.e18.

Fu-Shun Yen; Ming-Chih Hou; James Cheng-Chung Wei; Ying-Hsiu Shih; Chung Y Hsu; Chih-Cheng Hsu; Chii-Min Hwu

ABSTRACT · RESEARCH SUMMARY

Research summary

This matched cohort study using Taiwanese National Health Insurance data included 467 patient pairs. GLP-1 receptor agonist users had a lower risk of death (aHR 0.47; 95% CI 0.32–0.69), as well as fewer cardiovascular events, decompensated cirrhosis, hepatic encephalopathy, and hepatic failure. The findings apply to the studied population with type 2 diabetes and compensated cirrhosis and require further validation.

Key points based on the public abstract; this is a reading guide, not a full abstract translation.Read original abstract ↗